{ "symbol": "ARQT", "company": "Arcutis Biotherapeutics, Inc.", "generated_at": "2026-06-24T07:36:44.912Z", "event_count": 10, "events": [ { "type": "pipeline_event", "ts": "2026-06-20T15:08:13.700Z", "stage": "analyst", "outcome": "skip", "reason": "Score of 17 reflects absent insider conviction, high short interest (13.8%), and elevated RSI (72) into earnings. The active anti-signals (insider selling cluster, dilution, concentration) are valid and actionable; combined with Scout's range-bound verdict and lack of a clear income or directional edge, this dossier fails to clear the publication bar.", "trigger": "[form4_cluster] 10 Form 4 filings in last 14 days · 2 real trades", "source": "hunter" }, { "type": "analyst_decision", "ts": "2026-06-20T15:08:13.651Z", "skip": true, "reason": "Score of 17 reflects absent insider conviction, high short interest (13.8%), and elevated RSI (72) into earnings. The active anti-signals (insider selling cluster, dilution, concentration) are valid and actionable; combined with Scout's range-bound verdict and lack of a clear income or directional edge, this dossier fails to clear the publication bar.", "score": 17, "breakdown": { "smart_money": 0, "options_flow": 3, "catalyst": 5, "mispricing": 0, "quality": 5, "technical": 4 }, "debug_path": "drafts/2026-06-20-ARQT.analyst.debug.json" }, { "type": "scout_dossier", "ts": "2026-06-20T15:07:10.134Z", "summary": "Arcutis is a commercial-stage dermatology biotech with its lead product ZORYVE (topical roflumilast) posting 65% YoY revenue growth to $105M in Q1 FY26. The Form 4 cluster trigger was misleading — the 10 filings over 14 days were predominantly pre-scheduled 10b5-1 sales and RSU vesting transactions, not genuine insider conviction purchases. Patrick Heron's sole 'acquisition' was an RSU grant at $0 exercise price (not a cash purchase), while three directors collectively sold ~$240K under scheduled plans in May-June — all BELOW current prices ($22.99-$24.62 vs $26.21 spot). No open-market CEO/CFO/Director purchases of any material size were found. The bull case rests on strong ZORYVE growth, an analyst consensus target of $35 (+33% upside), FCF-positive status, and a pediatric label expansion catalyst via sNDA filing (PDUFA expected within 6-9 months). The bearish counter is that the Form 4 cluster was almost entirely scheduled selling (anti-signal per methodology), RSI is elevated at ~72 entering earnings (August 5), short interest is high at 13.8% of float, and the stock is already near its 52-week high with limited near-term re-rating catalysts beyond routine commercial execution.", "verdict": "range_bound_or_income", "confidence": 4, "tool_calls": 21, "walltime_min": 17, "debug_path": "dossiers/2026-06-20-ARQT.scout.debug.json" }, { "type": "analyst_decision", "ts": "2026-06-13T19:52:34.237Z", "skip": true, "reason": "Score falls well below the 45-point threshold due to zero smart-money or mispricing signals, lack of sustained bullish options flow, and unproven catalyst timing. The dossier explicitly flags a range-bound setup with revenue concentration and historical dilution risks, making it unsuitable for publication or paper-tracking at this time.", "score": 13, "breakdown": { "smart_money": 0, "options_flow": 0, "catalyst": 8, "mispricing": 0, "quality": 0, "technical": 5 }, "debug_path": "drafts/2026-06-13-ARQT.analyst.debug.json" }, { "type": "scout_dossier", "ts": "2026-06-13T19:51:31.749Z", "summary": "Arcutis is a commercial-stage dermatology biotech that has crossed into cash-flow positivity while posting 60%+ revenue growth on its ZORYVE (topical roflumilast) franchise. An sNDA for pediatric AD expansion (infants down to 3 months) was submitted in April 2026 and awaits FDA action — a material label expansion catalyst with only one competing non-steroidal option. All June 9 Form 4s were director RSU grants at $0 cost basis, not open-market purchases; no insider buying signal is present. Options flow shows a heavily bearish put/call ratio (4.17) on moderate volume, consistent with protective hedging by existing holders rather than new directional bets. The stock trades at ~21x forward P/E against 60%+ revenue growth — reasonable but not cheap — with analyst consensus near $35 vs current $24.38, implying the market has not fully priced in the pediatric label expansion upside or continued ZORYVE trajectory.", "verdict": "range_bound_or_income", "confidence": 4, "tool_calls": 19, "walltime_min": 12, "debug_path": "dossiers/2026-06-13-ARQT.scout.debug.json" }, { "type": "scout_dossier", "ts": "2026-06-09T15:48:42.378Z", "summary": "Arcutis is a commercial-stage dermatology biotech with ZORYVE franchise revenue growing 65% YoY ($105M Q1 2026) and approaching FCF breakeven. Multiple pediatric label expansions are pending (PDUFA June 29 for plaque psoriasis age 2-5, sNDA submitted April 2026 for atopic dermatitis down to 3 months). However, all recent insider transactions over the past 90 days are SELLs — exclusively tax-withholding and scheduled 10b5-1 sales on RSU vesting by CFO, CLO, CMO, and a board director. No open-market purchase (P-code) activity exists. The stock trades ~31% below its 52-week high of $31.77, below both the 50DMA ($22.51) and 200DMA ($23.66), suggesting technical deterioration from November's peak. While analyst consensus targets ~$35 (strong buy, 8 analysts), the absence of any insider buying conviction combined with a stock that is near fair value rather than dramatically mispriced makes this a hold-not-chase situation at current levels.", "verdict": "no_anomaly", "confidence": 5, "tool_calls": 20, "walltime_min": 19, "debug_path": "dossiers/2026-06-09-ARQT.scout.debug.json" }, { "type": "analyst_decision", "ts": "2026-05-23T06:30:38.570Z", "skip": true, "reason": "Critically low score due to zero insider buying, broken technicals, and absence of a near-term catalyst beyond August earnings. While elevated IV supports an income structure, the dossier flags concentration and dilution risks that outweigh the setup, and the lack of a directional edge makes publishing unjustified.", "score": 5, "breakdown": { "smart_money": 0, "options_flow": 0, "catalyst": 0, "mispricing": 0, "quality": 5, "technical": 0 }, "debug_path": "drafts/2026-05-23-ARQT.analyst.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-23T06:29:35.711Z", "summary": "Arcutis is a commercial-stage dermatology company whose lead product ZORYVE (topical roflumilast) delivered 65% YoY revenue growth in Q1 2026 ($105.4M). The pipeline trigger was a Form 4 cluster — however, every single filing examined from the May 2026 window represents routine tax-withholding sells via pre-set 10b5-1 plans by the CEO (3,172 shares), CLO (8,256 shares), CFO (1,341 shares), CMO (684 shares), and a director (7,144 shares). Zero open-market purchases. The stock collapsed ~34% from its November 2025 high ($31.20) to $20.86 following Q1 earnings that beat top-line but showed a large EPS miss driven by R&D investment. Analysts cluster at $34–36 targets — meaningful upside vs current price, but the near-term setup lacks urgency: stock below both 50- and 200-DMA, no insider buying signal, next catalyst is August earnings. IV runs 67–68% ATM, creating a viable covered-call / strangle income structure on rallies.", "verdict": "range_bound_or_income", "confidence": 4, "tool_calls": 24, "walltime_min": 17, "debug_path": "dossiers/2026-05-23-ARQT.scout.debug.json" }, { "type": "analyst_decision", "ts": "2026-05-16T01:43:15.200Z", "skip": true, "reason": "Dossier flags material anti-signals (single-product revenue concentration and dilution overhang) and lacks the quantitative catalysts, smart-money cluster, or technical momentum required to clear the scoring threshold; the elevated IV does not compensate for the asymmetric risk profile of a commercial-stage biotech with a binary FDA event and no structural earnings tailwind.", "score": 8, "breakdown": { "smart_money": 0, "options_flow": 0, "catalyst": 8, "mispricing": 0, "quality": 0, "technical": 0 }, "debug_path": "drafts/2026-05-16-ARQT.analyst.debug.json" }, { "type": "scout_dossier", "ts": "2026-05-16T01:42:34.091Z", "summary": "Arcutis reported strong Q1 2026 net product revenue of $105.4M (+65% YoY) and turned cash-flow positive for the first time in company history ($2.2M operating CF). However, shares dropped ~11% post-earnings on a guidance-related selloff that appears overdone relative to confirmed fundamentals. Seven Form 4 filings in 14 days cluster around May 4 and May 11, with multiple insiders buying open-market at $21-$22 — precisely near the bottom of this drawdown from the 52-week high of $31.77. A pending FDA sNDA for ZORYVE cream expansion to infants as young as 3 months (submitted April 27) represents a named catalyst that could re-rate the stock, and several Wall Street analysts are clustering around $34-35 targets. The stock is below both its 50DMA and 200DMA with RSI in neutral territory (~41), consistent with accumulation rather than distribution.", "verdict": "range_bound_or_income", "confidence": 4, "tool_calls": 21, "walltime_min": 12, "debug_path": "dossiers/2026-05-16-ARQT.scout.debug.json" } ], "lessons": [], "chart_signal": { "ticker": "ARQT", "call": "BUY", "confidence": 5, "score": 7, "factors": { "above_200dma": "+2", "above_50dma": "+1", "momentum_strong_up": "+2 (46.6%)", "rsi_neutral": "0 (69.6)", "macd_above_signal": "+1", "recent_macd_bullish_cross": "+1 (18d ago)", "from_high": "0 (-15.8%)" }, "summary": "BUY (score +7) · 12-1 mom 46.6% · RSI 69.6 · above_both · -15.8% from high", "last_close": 26.27, "one_month_ago_close": 21.01, "twelve_month_ago_close": 14.33, "twelve_one_momentum_pct": 46.62, "rsi_14": 69.6, "ma_stack": "above_both", "from_period_high_pct": -15.8, "period_high": 31.2, "price_targets": { "bear": 21.84, "fair": 27.92, "bull": 36, "bear_return_pct": -16.9, "fair_return_pct": 6.3, "bull_return_pct": 37, "method": "street_targets ⨯ chart_floors", "street": { "target_low": 33, "target_mean": 34.625, "target_high": 36, "analyst_count": 8 } }, "generated_at": "2026-06-24T07:36:44.907Z" } }